J&J, Bristol Myers race to amplify CAR-T manufacturing to meet label expansion in multiple myeloma

John­son & John­son and Bris­tol My­ers Squibb are in­di­vid­u­al­ly gear­ing up their lentivi­ral pro­duc­tion and CAR-T prod­uct ca­pac­i­ties fol­low­ing their re­cent la­bel ex­pan­sions in mul­ti­ple myelo­ma.

J&J, along­side part­ner Leg­end Biotech, has its eyes on dou­bling its Carvyk­ti ca­pac­i­ty by the end of 2024, said Kim­ber­ly Loun­ds Fos­ter, J&J vice pres­i­dent for ad­vanced ther­a­pies sup­ply chain, in an in­ter­view with End­points News. Carvyk­ti has been ad­min­is­tered in over 2,700 pa­tients so far, she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.